May is National Skin Cancer and Melanoma Awareness Month. Learn about the latest advances and research in skin cancer and melanoma.
2023
Dr Sriramareddy on the Relationship Between Uveal Melanoma and the Liver Metastases
Sathya Neelature Sriramareddy, MD, PhD, postdoctoral fellow, Moffitt Cancer Center, discusses how the interaction between uveal melanoma cells and the liver microenvironment could influence metastasis growth and therapeutic response.
Krista Rubin Breaks Down Best Practices With Tebentafusp for Uveal Melanoma
In this episode of The Vitals, Krista M. Rubin, RN, MS, FNP-BC, joins Oncology Nursing News® to discuss best nursing practices with tebentafusp-tebn (Kimmtrak) for patients with unresectable or metastatic uveal melanoma. Rubin is a nurse practitioner with the Center for Melanoma at Massachusetts General Hospital, with over 20 years of experience caring for patients with melanoma. She is also the chair of the Melanoma Nursing Initiative.
Early ctDNA Testing Provides Another Tool for Predicting Survival Outcomes With Tebentafusp in Metastatic Uveal Melanoma
The incorporation of circulating tumor DNA (ctDNA) testing into standard practice for patients with metastatic uveal melanoma receiving tebentafusp-tebn (Kimmtrak) may provide a more accurate assessment of the agent’s efficacy compared with radiographic response, and better inform the decision to continue or discontinue treatment, according to Ryan J. Sullivan, MD.